Press Releases

Date Title and Summary Additional Formats
Toggle Summary Amicus Therapeutics Appoints Burke W. Whitman to its Board of Directors
CRANBURY, N.J. , May 13, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced the election and appointment of Burke W. Whitman to its Board of Directors, effective at the end of this quarter. Mr. Whitman is a proven leader of corporate and military organizations.  He has
View HTML
Toggle Summary Amicus Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference
CRANBURY, N.J. , May 10, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley , Chairman and Chief Executive Officer, will participate in a fireside chat at the Bank of America Merrill Lynch 2019 Health Care Conference in Las Vegas, NV on Tuesday, May 14,
View HTML
Toggle Summary Amicus Therapeutics Announces First Quarter 2019 Financial Results and Corporate Updates
1Q19 Galafold ® (m igalastat) Strong Launch Trends Continue with Largest Quarterly Number of Net New Patients Added Globally (150+ Net New Galafold Patients in 1Q19) 1Q19 Galafold Revenue of $34.0M and Early 2Q19 Momentum on Key Launch Metrics Maintaining FY19 Revenue Guidance of $160M-$180M and
View HTML
Toggle Summary Amicus Therapeutics Presents Positive Preclinical Pompe Disease Gene Therapy Data at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting
Preclinical Studies Show Robust Uptake and Glycogen Reduction in Multiple Tissues, Including Brain and Spinal Cord Initial Validation for Collaboration Combining Amicus-Engineered Transgenes with Penn’s AAV Gene Therapy Technologies Significant and Broad New Amicus Platform Technology with
View HTML
Toggle Summary Amicus Therapeutics to Announce First Quarter 2019 Financial Results on May 8, 2019
CRANBURY, N.J. , April 25, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, May 8, 2019 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2019 .
View HTML
Toggle Summary Amicus Therapeutics to Present Preclinical Pompe Disease Gene Therapy Data at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting
CRANBURY, N.J. , April 15, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced the company will present initial preclinical data from its investigational adeno-associated viral (AAV) gene therapy program for Pompe disease in a poster at the American Society of Gene & Cell
View HTML
Toggle Summary Amicus Therapeutics Issued Two U.S. Patents for Pompe Enzyme ATB200
New Intellectual Property Covers Composition of Matter and Manufacturing Method out to Mid-2030s CRANBURY, N.J. , March 20, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the United States Patent and Trademark Office has issued two new patents directed to the
View HTML
Toggle Summary Amicus Therapeutics Announces Full-Year 2018 Financial Results and 2019 Corporate Updates
Continued Strong Galafold Launch Trends in Early 2019 - On Track to Achieve FY19 Revenue Guidance of $160M-$180M FY18 Galafold Revenue of $91.2M Reflects 650+ Fabry Patients Treated at end of 2018 - 1,000+ Patients Expected by end of 2019 Clinical Data Out to Month 24 and Breakthrough Therapy
View HTML
Toggle Summary Amicus Establishes Global Research and Gene Therapy Center of Excellence in Philadelphia
New 75,000 sq. ft. State of the Art Facility in uCity Square Adjacent to Penn Campus Strengthens Amicus Capabilities as a Leading Global Rare Disease Biotechnology Company CRANBURY, N.J. and PHILADELPHIA , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced it is
View HTML
Toggle Summary U.S. FDA Grants Breakthrough Therapy Designation (“BTD”) to Amicus’ AT-GAA in Late Onset Pompe Disease
First BTD Granted for a Second Generation Lysosomal Storage Disorder Therapy First BTD for an Investigational Treatment in Pompe Disease CRANBURY, N.J. , Feb. 25, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S.
View HTML